Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Lenze, E. J. Articles by Reynolds, C. F. Search for Related Content PubMed Citation Articles by Lenze, E. J. Articles by Reynolds, C. F., III Geriatric Psychiatry Anxiety Disorders (General) Antidepressants Anxiolytics

Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial

OBJECTIVE: Anxiety disorders are highly prevalent in elderly persons. However, to date, the efficacy of selective serotonin reuptake inhibitors (SSRIs) for the treatment of anxiety disorders in this age group has not been established. METHOD: Thirty-four participants age 60 and older with a DSM-IV anxiety disorder (mainly generalized anxiety disorder) and a Hamilton Anxiety Rating Scale score of 17 or higher were randomly assigned under double-blind conditions to either citalopram or placebo. Response was defined as a score of 1 (very much improved) or 2 (much improved) on the Clinical Global Improvement scale or a 50% reduction in the Hamilton anxiety scale score. Response and side effects with citalopram and placebo were compared by using chi-square tests and linear modeling. RESULTS: Eleven (65%) of the 17 citalopram-treated participants responded by 8 weeks, versus four (24%) of the 17 placebo-treated participants. The most common and problematic side effect in the citalopram group was sedation. CONCLUSIONS: The authors believe this to be the first prospective controlled study to test the efficacy of an SSRI in the management of anxiety disorders among the elderly. These results support the efficacy of citalopram in late-life anxiety disorders. They need to be replicated in a larger study group.

This article has been cited by other articles:

				E. J. Lenze, B. L. Rollman, M. K. Shear, M. A. Dew, B. G. Pollock, C. Ciliberti, M. Costantino, S. Snyder, P. Shi, E. Spitznagel, et al. Escitalopram for Older Adults With Generalized Anxiety Disorder: A Randomized Controlled Trial JAMA, January 21, 2009; 301(3): 295 - 303. [Abstract] [Full Text] [PDF]

				S. Montgomery, K. Chatamra, L. Pauer, E. Whalen, and F. Baldinetti Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder The British Journal of Psychiatry, November 1, 2008; 193(5): 389 - 394. [Abstract] [Full Text] [PDF]

				D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol, November 1, 2005; 19(6): 567 - 596. [Abstract] [PDF]

				S. P. KRUSZEWSKI Conclusions Inconsistent With Results With Citalopram Am J Psychiatry, November 1, 2005; 162(11): 2195 - 2196. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us